

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF CALIFORNIA

ALLERGIA, INC., a California
corporation,

Plaintiff,

v.

DENIS BOUBOULIS, an individual; and
DOES 1 THROUGH 5, inclusive,

Defendants.

Case No.: 14-CV-1566 JLS (RBB)

**ORDER DENYING DEFENDANT’S
MOTION FOR ADVANCEMENT OF
LEGAL EXPENSES**

(ECF No. 59)

Presently before the Court is Defendant Denis Bouboulis’ Motion for Advancement of Legal Expenses. (“Mot.,” ECF No. 59.) Also before the Court is Plaintiff Allergia, Inc.’s Response in Opposition to, (“Opp’n,” ECF No. 62), and Defendant’s Reply in Support of, (“Reply,” ECF No. 64), Defendant’s Motion. Plaintiff also filed an untimely supplemental response in opposition. (“Supp. Opp’n,” ECF No. 63.) The Court vacated the hearing on the Motion scheduled for August 25, 2016 pursuant to Civil Local Rule 7.1(d)(1). (ECF No. 65.) After considering the parties’ arguments and the law, the Court **DENIES** Defendant’s Motion for Advancement of Legal Expenses.

///
///

1 **BACKGROUND**

2 Beginning several years ago, Defendant worked with Plaintiff’s predecessor-in-
3 interest, CLRS Technology, Inc., to develop and invent medical devices and related
4 methods for using phototherapeutics to alleviate the symptoms of allergic rhinitis. (Second
5 Amended Complaint (“SAC”) ¶ 9, ECF No. 53.) In exchange for these contributions,
6 Defendant received 116,111 shares of CLRS common stock. (*Id.*)

7 On August 5, 2010, CLRS filed a provisional patent application with the United
8 States Patent and Trademark Office (USPTO), Application Ser. No. 61/371,172 (the “’172
9 Application”), directed to an invention for alleviating the symptoms of allergic rhinitis.
10 (*Id.* ¶ 10.) Defendant was one of three named inventors. (*Id.*)

11 Approximately two months later, CLRS spun out ownership of the ’172 Application
12 to Plaintiff in connection with a corporate transaction involving a third party, Solta. (*Id.*
13 ¶ 11.) Accordingly, Plaintiff was incorporated on October 5, 2010 under the laws of
14 California. (*Id.* ¶ 12.) All of the then-existing shareholders of CLRS—including
15 Defendant—received shares of stock in Plaintiff based on their then-existing shares in
16 CLRS. (*Id.*) Defendant was made Plaintiff’s President. (*See id.* ¶ 16.)

17 CLRS then assigned all its rights in the ’172 Application to Plaintiff. (*Id.* ¶ 13.) On
18 October 12, 2010, Defendant signed the Assignment and Assumption Agreement (the
19 “Assignment Agreement”) on behalf of Plaintiff. (*Id.* ¶¶ 14–15.) The Assignment
20 Agreement provided that “Assignor [CLRS] owns all of the assets set forth on Exhibit A
21 attached hereto (the “Distributed Assets”) . . . [.]” (*id.* ¶ 15(a) (emphasis in original)), which
22 included the ’172 Application, (*id.* ¶ 15(d)). Pursuant to the Assignment Agreement, CLRS
23 and Plaintiff desired to effect “the sale, assignment, transfer, conveyance, distribution and
24 delivery of all of Assignor’s rights, title and interest in, to or under the Distributed Assets
25 to Assignee [. . . Allergia]” and, “at the request of a party [to the Agreement] and without
26 further consideration, the other party . . . shall execute and deliver . . . such other
27 instruments of assignment . . . as such party may reasonably request to effect the
28 distribution by [CLRS] of the Distributed Assets.” (*Id.* at ¶¶ 15(b), (c)). On October 13,

1 2010, Defendant also signed the License Agreement on behalf of Plaintiff. (*Id.* at ¶¶ 16–
2 17.) The License Agreement expressly represented that CLRS “hereby assigned to
3 [Plaintiff] all right, title and interest in and to the ATD Patent Rights,” which was defined
4 as including the ’172 Application. (*Id.* ¶¶ 17(a), (c).)

5 When signing the Assignment and License Agreements, “Defendant was fully aware
6 of the contents of the documents . . . , and was fully aware of the purpose and intent of
7 those documents.” (*Id.* ¶ 18.) “Defendant gave no indication to Plaintiff . . . that Defendant
8 believed that CLRS and then [Plaintiff] did not own all of the ’172 [Application] and
9 related rights, and/or that Defendant believed that he had not assigned his rights therein to
10 CLRS and then/thereby to [Plaintiff].” (*Id.* ¶ 19.) Indeed, “for at least many months . . . ,
11 Defendant . . . did not tell or indicate to [Plaintiff] . . . that Defendant . . . believed that he
12 personally retained any ownership in the ’172 [Application] and related rights,” but rather
13 he “remained silent on the issue.” (*Id.* ¶ 24.)

14 On October 15, 2010, the initial incorporator of Plaintiff formally named Defendant
15 as an initial director of Plaintiff. (*Id.* ¶ 20.) On that same date, the CLRS/Solta transaction
16 was executed. (*Id.* ¶ 21.) The resulting Agreement and Plan of Merger (the Executive
17 Summary) and Disclosure Schedule expressly referenced the Assignment and License
18 Agreements. (*Id.* ¶¶ 21–22.)

19 A few months later, Defendant requested a telephone conference with the owners
20 and directors of Plaintiff, during which he disclosed an outline of a strategic business plan
21 for Plaintiff. (*Id.* ¶ 27.) Defendant proposed that he would undertake execution of the
22 proposed plan and assume the duties of CEO of Plaintiff if he were granted a controlling
23 stake in the capital stock of Plaintiff. (*Id.*) In response, the shareholders and directors of
24 Plaintiff requested that Defendant prepare and present a budget for his proposal. (*Id.* ¶ 28.)
25 Several months passed without Defendant making the requested presentation. (*Id.*)
26 Instead, Defendant “secretly prepared a related and apparently competitive patent
27 application . . . without the knowledge and/or authorization of [Plaintiff] or its other
28 shareholders.” (*Id.* ¶ 29.) Defendant continued as President and director of Plaintiff until

1 approximately May 2011. (*Id.* ¶ 30.)

2 On August 4, 2011, Plaintiff filed a full utility application, Ser. No. 13/198,672 (the
3 “’672 Application”). (*Id.* ¶ 34.) Although Plaintiff solicited Defendant’s signature on
4 related filings, Defendant refused to participate or assist in the prosecution of the ’672
5 Application. (*Id.*)

6 On August 5, 2011, Defendant secretly filed Application Ser. No. US 13/204,282
7 (the ’282 Application). (*Id.* ¶¶ 29, 35.) The ’282 Application “is so closely related to [the
8 ’172 Application] that it may foreseeably interfere with or negatively affect [Plaintiff]’s
9 business efforts related to [Plaintiff]’s patent-pending technology.” (*Id.* ¶ 29.) Defendant
10 filed a related Patent Cooperation Treaty patent application, Ser. No. PCT/US12/049108
11 (the “’108 Application”), on August 1, 2012, and a related European Union application,
12 Ser. No. 2,739,354 (the “’354 Application”), on February 26, 2014. (*Id.* ¶ 36.)
13 “Defendant’s patent applications include description and claims that are similar or even
14 virtually identical to the description and claims . . . in the Plaintiff’s pending patent
15 applications.” (*Id.* ¶ 37.)

16 Plaintiff subsequently has “continued to make reasonable efforts to get Defendant to
17 sign certain formal ‘assignment’ documents related to the ’172 [Application],” but
18 Defendant has refused. (*Id.* ¶ 39.) “[P]otential investors in Plaintiff’s ’172 patent-pending
19 technologies and related opportunities have declined to invest based on Defendant[’s] . . .
20 actions, including positions taken and communicated to those investors by Defendant . . .
21 regarding the parties’ respective rights regarding Plaintiff’s ’172 patent-pending
22 technologies and related opportunities.” (*Id.* ¶ 40.)

23 On June 30, 2014, Plaintiff filed its initial complaint, asserting two causes of action:
24 (1) declaratory judgment of patent application ownership and/or other patent and
25 intellectual property rights, and (2) breach of fiduciary duty. (*See* ECF No. 1.) On August
26 17, 2015, the Court dismissed Plaintiff’s first cause of action to the extent it attempted to
27 correct ownership of the ’282 Application and its second cause of action for breach of
28 fiduciary duty. (*See* ECF No. 28.) Plaintiff filed its FAC on September 4, 2015 (*see* ECF

1 No. 30), and on May 19, 2016 the Court dismissed Plaintiff's causes of action for breach
2 of contract and fraud. (*See* ECF No. 51.)

3 On June 3, 2016, Plaintiff filed its SAC, alleging causes of action for (1) declaratory
4 judgment of patent application ownership and/or other patent and intellectual property
5 rights; (2) breaches of fiduciary duty and/or implied contract; and (3) fraud.

6 Defendant now moves this Court for advancement of legal expenses because
7 Defendant argues that Plaintiff sued him in his capacity as a former officer or director of
8 Plaintiff, and thus he is entitled to an advancement of fees pursuant to California
9 Corporations Code section 317 and Plaintiff's Bylaws. The indemnification provision of
10 Plaintiff's Bylaws states:

11 **Section 6.1. Right to Indemnification.** The Corporation shall
12 indemnify and hold harmless, to the fullest extent permitted by
13 applicable law as it presently exists or may hereafter be amended,
14 any person who was or is made or is threatened to be made a
15 party or is otherwise involved in any action, suit or proceeding,
16 whether civil, criminal, administrative or investigative (a
17 "proceeding") by reason of the fact that he, or a person for whom
18 he is the legal representative, is or was a director or officer of the
19 Corporation or is or was serving at the request of the Corporation
20 as a director, officer, employee or agent of another corporation
21 or of a partnership, joint venture, trust, enterprise or nonprofit
22 entity, including service with respect to employee benefit plans,
23 against all liability and loss suffered and expenses (including
attorneys' fees) reasonably incurred by such person. The
Corporation shall be required to indemnify a person in
connection with a proceeding (or part thereof) initiated by such
person only if the proceeding (or part thereof) was authorized by
the Board of Directors of the Corporation.

24 (Mot. Ex. B ("Bylaws") 8,¹ ECF No. 59-4.)

25 ///

26 ///

27 _____

28 ¹ Pin citations refer to the CM/ECF numbers stamped electronically at the top of each page.

1 Plaintiff's Bylaws also provide an advancement provision, which states:

2 **Section 6.2. Prepayment of Expenses.** The Corporation shall
3 pay the expenses (including attorneys' fees) incurred by a
4 director or officer in defending any proceeding in advance of its
5 final disposition, provided, however, that, to the extent required
6 by law, such payment of expenses incurred by a director or
7 officer in advance of the final disposition of the proceeding shall
8 be made only upon receipt of an undertaking by the director or
9 officer to repay all amounts advanced if it should be ultimately
determined that the director or officer is not entitled to be
indemnified under this Article or otherwise.

10 (*Id.*) Section 6.3 of the Bylaws further explains what a claimant must do if he is not
11 indemnified in full within sixty days of his written claim for indemnification. (*Id.*)

12 LEGAL STANDARD

13 California Corporations Code section 317 provides mechanisms for permissive and
14 mandatory indemnification by the corporation, as well as provisions for advancement of
15 expenses. Of issue here is the indemnification provision of subsection (c), which provides
16 that

17 [a] corporation shall have power to indemnify any person who
18 was or is a party or is threatened to be made a party to any
19 threatened, pending, or completed action by or in the right of the
20 corporation to procure a judgment in its favor by reason of the
21 fact that the person is or was an agent of the corporation, against
22 expenses actually and reasonably incurred by that person in
23 connection with the defense or settlement of the action if the
24 person acted in good faith, in a manner the person believed to be
25 in the best interests of the corporation and its shareholders.

26 Cal. Corp. Code § 317(c).

27 Subsection (f) further allows a corporation to advance fees in such cases:

28 [e]xpenses incurred in defending any proceeding may be
advanced by the corporation prior to the final disposition of the
proceeding upon receipt of an undertaking by or on behalf of the
agent to repay that amount if it shall be determined ultimately

1 that the agent is not entitled to be indemnified as authorized in
2 this section. The provisions of subdivision (a) of Section 315 do
3 not apply to advances made pursuant to this subdivision.

4 *Id.* at § 317(f).

5 ANALYSIS

6 Defendant broadly argues that he is entitled to advancement of his fees based on
7 section 317(f) and Plaintiff's Bylaws. (*See generally* Mot., ECF No. 59-1.) Plaintiff
8 responds that (1) Defendant is not entitled to advancement because he does not meet the
9 requirements of indemnification pursuant to section 317(c), on which Plaintiff believes the
10 advancement provision of section 317(f) is necessarily based, (Opp'n 11-13, ECF No. 62);
11 (2) advancement would be unfair given Defendant's "extensive delay and litigation
12 tactics," (*id.* at 13–14); (3) public policy should not permit advancement in this instance,
13 (*id.* at 14–16); (4) Defendant's status as an officer or director of the company is irrelevant
14 to "Plaintiff's main claims," (*id.* at 7–11); and (5) in the alternative, Plaintiff should be
15 allowed to amend its complaint "to withdraw its claim for any rights under Defendant's
16 other 'secret' patent applications," (*id.* at 16–17). The Court considers each argument in
17 turn.

18 **I. Relationship Between Sections 317(c) (Indemnification) and 317(f)** 19 **(Advancement)**

20 Defendant argues that sections 317(c) and 317(f) are conceptually and procedurally
21 separate provisions. (Mot. 13–16, ECF No. 59-1.) According to Defendant, section 317
22 indemnification is not available "until there has been either a determination of whether the
23 corporate agent was acting in good faith or an adjudication on the merits." (*Id.*) On the
24 other hand, Defendant argues that advancement is a summary proceeding "that occurs
25 *before* any adjudication on the merits of the case against the corporate director or officer
26 and before any determination of 'good faith.'" (*Id.* (emphasis in original).) "In other
27 words, the right to advancement *does not depend on* whether the corporate agent is
28 ultimately found to be entitled to indemnification." (*Id.* at 14 (emphasis in original).)

1 Plaintiff responds that, to the contrary, the advancement provision of section 317(f)
2 necessarily depends on section 317(c), and thus Defendant is not entitled to any
3 advancement because “there is no basis upon which he will ever be able to show that his
4 relevant actions . . . met the requirements for indemnification under 317(c).” (Opp’n 13,
5 ECF No. 62 (emphasis removed).)

6 Whether the advancement provision of section 317(f) is conceptually and
7 procedurally separate from section 317(c) appears to be a matter of first impression in
8 California. “When interpreting a statute, we look to the plain meaning of the statute’s
9 words, which are generally the most reliable indicator of the Legislature’s intent.”
10 *Nicholas Labs., LLC v. Chen*, 199 Cal. App. 4th 1240, 1249 (2011) (citing *Cassady v.*
11 *Morgan, Lewis & Bockius LLP*, 145 Cal. App. 4th 220, 231 (2006)).

12 Here, a plain reading of the statute supports Defendant’s view that the provisions are
13 conceptually and procedurally separate. The indemnification provisions require either an
14 ultimate determination that the agent was acting in good faith or an adjudication on the
15 merits. Subject to a few exceptions, section 317(c) broadly allows a corporation to
16 indemnify a corporate director or officer in any action “by reason of the fact” that they
17 were an agent of the corporation and an ultimate showing that they “acted in good faith, in
18 a manner the person believed to be in the best interests of the corporation and its
19 shareholders.” Cal. Corp. Code § 317(c). In addition, indemnification is mandatory under
20 section 317(d) if “a corporate agent has been successful on the merits in defense of any
21 proceeding referred to in subdivision (b) or (c) or in defense of any claim, issue, or matter
22 therein,” without regard to the officer’s good faith. *Id.* § 317(d). Thus, indemnification
23 under section 317 requires either a determination of the agent’s good faith or an
24 adjudication of success on the merits.

25 The advancement provision, in contrast, does not require any such determination.
26 While certainly related to the indemnification provisions, section 317(f) provides that any
27 such funds “may be advanced by the corporation *prior to the final disposition of the*
28 *proceeding.*” Cal. Corp. Code § 317(f) (emphasis added). Because advancement is

1 permissive (i.e., a corporation “may” advance these funds), all that is required to satisfy
2 this subdivision is (1) corporate authorization for advancement (e.g., an advancement
3 provision in the corporation’s bylaws) and (2) “an undertaking by or on behalf of the agent
4 to repay that amount if it shall be determined ultimately that the agent is not entitled to be
5 indemnified as authorized in this section.”² *Id.* Thus, whether or not the agent is ultimately
6 indemnified pursuant to section 317(c) has no bearing on whether the corporation has
7 authorized an advancement of those funds pursuant to subdivision (f).

8 The Court’s view of the statute comports with other jurisdictions that have
9 considered the same issue. *See, e.g., Kaung v. Cole Nat. Corp.*, 884 A.2d 500, 509 (Del.
10 2005)³ (“An advancement action is a summary proceeding. The statutory authorization for
11

12
13 ² The Ninth Circuit also appears to agree with this view. *Cf. Johnson v. Couturier*, 572 F.3d 1067, 1078
14 (9th Cir. 2009) (noting that under section 317(f) “California allows advancement of defense costs upon
15 receipt of an undertaking,” and finding that but-for preemption under ERISA, director-defendants, who
16 were accused of corporate wrongdoing, “all submitted the requisite undertakings, thus apparently
17 rendering advancement of their defense costs enforceable under state law”).

18 ³ In the absence of guidance from California courts, the Court finds Delaware law on advancement
19 particularly persuasive because of the depth of its experience with corporate governance issues. *See, e.g.,*
20 *Int’l Airport Centers, L.L.C. v. Citrin*, 455 F.3d 749, 752 (7th Cir. 2006) (Posner, J.) (“What is true is that
21 ‘advancement’ is rather a Delaware specialty”); Stephen A. Radin, “Sinners Who Find Religion”:
22 *Advancement of Litigation Expenses to Corporate Officials Accused of Wrongdoing*, 25 Rev. Litig. 251,
23 251–52 (2006) (“Recent decisions in Delaware—‘the Mother Court of corporate law’ and the state whose
24 ‘rich abundance of corporate law’ guides courts throughout the country due to ‘the special expertise and
25 body of case law developed in the Delaware Chancery Court and the Delaware Supreme Court’—address
26 an important but infrequently discussed corporate governance issue: charter, bylaw, and indemnification
27 or employment agreement provisions that mandate advancement of attorneys’ fees and other defense costs
28 for corporate directors, officers, and employees accused of wrongdoing by the corporation or by federal
or state law authorities.” (citations omitted)). Indeed, several other states interpreting their own
advancement and indemnification statutes have found Delaware law persuasive. *See, e.g., Kramer v.*
Liberty Prop. Trust, 408 Md. 1, 24–25 (2009) (“Due to [the similarity between both states’ advancement
statutes], and because the Delaware courts have gained a reputation for their expertise in matters of
corporate law, we deem decisions of the Delaware Supreme Court and Court of Chancery to be highly
persuasive as to our interpretation of what constitutes a ‘proceeding’ within the meaning of § 2-418
[Maryland’s advancement statute.]”); Radin, *supra*, at 271 (“To the limited extent that there is law
[regarding advancement] outside Delaware, it is the same as the law in Delaware.”).

In addition, the Delaware corporate code provision providing for advancement is nearly the same
as California’s. *Compare* Cal. Corp. Code § 317(f), *with* Del. Corp. Code § 145(e); *cf. Oakland Raiders*
v. Nat’l Football League, 93 Cal. App. 4th 572, 586 n.5 (2001) (“The parties agree that we may properly

1 interim advancement of litigation expenses is distinct from the right to receive final
2 indemnification under Section 145(a) and (b) of the DGCL.”); *see also Miller v. Miller*,
3 132 Ohio St. 3d 424, 429 (2012) (holding that, as a matter of first impression, “[a]lthough
4 advancement and indemnification are corollaries, they are not one and the same”); *Ficus*
5 *Investments, Inc. v. Private Capital Mgmt., LLC*, 61 A.D.3d 1, 9, 872 N.Y.S.2d 93 (2009)
6 (citing Delaware law as instructive and holding that indemnification and advancement are
7 “independent of one another, in that ‘an advancement proceeding is summary in nature and
8 not appropriate for litigating indemnification or recoupment’” (citation omitted)). Thus,
9 the Court rejects Plaintiff’s argument that Defendant’s right to advancement depends on
10 whether he will eventually be indemnified. *See Heine v. Bank of Oswego*, 144 F. Supp. 3d
11 1198, 1206 (D. Or. 2015) (citing Richard A. Rossman, Matthew J. Lund, and Kathy K.
12 Lochmann, *A Primer of Advancement of Defense Costs: The Rights and Duties of Officers*
13 *and Corporations*, 85 U. Det. Mercy L. Rev. 29, 53 (2007) (“Advancement generally refers
14 to the right of a director or officer to receive an advance for expenses that he or she incurs
15 in the legal proceeding before its final disposition. A director or officer’s entitlement to an
16 advancement of expenses is related to his or her entitlement to indemnification; however,
17 the eligibility requirements for each are distinct.”), *Holley v. Nipro Diagnostics, Inc.*, No.
18 CA 9679-VCP, 2014 WL 7336411, at *10 (Del. Ch. Dec. 23, 2014) (“[I]ndemnification
19 and advancement ‘are separate and distinct legal actions’ and . . . the ‘right to advancement
20 is not dependent on the right to indemnification.’” (citation omitted)). Accordingly, the
21 Court holds that advancement under section 317(f) is separate and distinct from the
22 indemnification subdivisions of section 317, and thus an agent is entitled to advancement
23 under subdivision (f) if advancement is provided for by the corporation and the agent
24 provides an undertaking to repay the advancement in the event he is not entitled to
25 indemnification under section 317.

26 _____
27 rely on corporate law developed in the State of Delaware given that it is identical to California corporate
28 law for all practical purposes.”).

1 **II. Whether Defendant Is Entitled to Advancement**

2 The Court now turns to whether Defendant is entitled to advancement in this case.
3 As just discussed, Defendant’s claim for advancement depends on whether (a) Plaintiff
4 provided Defendant with a right to advancement and (b) Defendant has provided an
5 undertaking to repay the advancement in the event he is not entitled to indemnification.
6 Because the Court concludes Defendant has no right to advancement, even though
7 Plaintiff’s Bylaws contain an advancement provision, the Court does not address whether
8 Defendant has provided an undertaking to repay the advancement.

9 As noted above, Plaintiff’s Bylaws expressly provide for indemnification and
10 advancement.⁴ As to indemnification, Section 6.1 states that the “Corporation shall
11 indemnify and hold harmless, to the fullest extent permitted by applicable law as it
12 presently exists or may hereafter be amended, any person . . . by reason of the fact that
13 he . . . is or was a director or officer of the Corporation” (Bylaws 8, ECF No. 59-4.)
14 The advancement provision of Section 6.2 is mandatory and unconditional, providing that,
15 subject to a few exceptions, the Corporation “shall pay the expenses (including attorneys’
16 fees) incurred by a director or officer in defending any proceeding in advance of its final
17 disposition” (*Id.*) The indemnification provision of the Bylaws, on which the
18 advancement provision is based, provides for a scope of indemnification to the fullest
19 extent of the law, which both parties agree triggers the requirements of section 317. (*See*
20 *generally* Mot., ECF No. 59-1; Opp’n, ECF No. 62.) Both the indemnification and
21 advancement provisions require the requesting party to be or have been a director or officer
22 of the Corporation. Thus, whether Defendant is entitled to advancement of his fees
23 depends in part on whether he was sued “by reason of the fact that” he was an agent, officer,
24

25
26 ⁴ “It is generally accepted that corporate bylaws are to be construed according to the general rules
27 governing the construction of statutes and contracts. Bylaws must be given a reasonable construction and,
28 when reasonably susceptible thereof, they should be given a construction which will sustain their
validity” *Singh v. Singh*, 114 Cal. App. 4th 1264, 1294 (2004) (internal quotation marks omitted)
(citing *Sanchez v. Grain Growers Ass’n*, 126 Cal. App. 3d 665, 672 (1981)).

1 or director of Plaintiff.⁵

2 In order to be indemnified under section 317, the action must have been brought
3 against the party “by reason of the fact that the person is or was an agent of the
4 corporation.” Cal. Corp. Code § 317 (b), (c). Courts in other jurisdictions look to the
5 allegations in the complaint when conducting the “by reason of the fact” advancement
6 analysis. *See, e.g., Holley v. Nipro Diagnostics, Inc.*, No. CA 9679-VCP, 2014 WL
7 7336411, at *8 (Del. Ch. Dec. 23, 2014) (“[T]he ‘by reason of the fact’ analysis requires
8 looking to the allegations in the SEC’s complaint.”). While California law appears to be
9 silent on how to apply the “by reason of fact” analysis in the advancement context,
10 California courts have applied this standard to indemnification. Specifically, “by reason
11 of the fact that the person is or was an agent of the corporation” would not apply, and thus
12 indemnification is not warranted, “[w]here personal motives, not the corporate good, are
13 predominant in a transaction giving rise to an action.” *Plate v. Sun-Diamond Growers*,
14 225 Cal. App. 3d 1115, 1123 (1990). “In other words, the conduct of the agent which
15 gives rise to the claim against him must have been performed in connection with his
16 corporate functions and not with respect to purely personal matters.” *Id.* (citation
17 omitted). “For example, ‘[i]t would . . . appear unlikely that an officer could properly claim
18 that he was entitled to indemnification as the result of litigation brought to recover short-
19 swing profits or profits from trading in the stock of his corporation on the basis of inside
20 information’” *Id.* (citation omitted). Accordingly, the Court will apply this reasoning
21 in the advancement context.⁶

22
23 ⁵ *See, e.g.,* Mot. 7, ECF No. 59-1 (“At this stage, and for purposes of this summary advancement
24 proceeding, the Court need only assess whether [Plaintiff’s] claims against [Defendant] were asserted
25 against him in his capacity as a corporate agent.”); *see also Homestore, Inc. v. Tafeen*, 888 A.2d 204, 213–
26 14 (Del. 2005) (finding that the advancement provision at issue was mandatory and unconditional and still
holding a “narrow proceeding” to determine whether the party was sued in his official capacity).

27 ⁶ The Court notes that its conclusions might have varied if it applied Delaware law interpreting the “by
28 reason of the fact” standard in the advancement context. In particular, Delaware law appears to be broader
than California law addressing the standard in the indemnification context. Specifically, the Delaware
Supreme Court explained that, in the advancement context, “if there is a nexus or causal connection

1 The California Court of Appeal’s decision in *Plate v. Sun-Diamond Growers* is
2 instructive in this case. In *Plate*, defendants Branson and McElroy were officers of Sun-
3 Diamond Growers, an administrative and sales organization for roughly sixty thousand
4 growers, who initially worked with H&R Plate & Company, Inc. (“Plate”), an industrial
5 commodity food broker who was the exclusive broker for Sun-Diamond products in
6 Northern California. *Id.* at 119. After some time, these defendants decided to leave Sun-
7 Diamond and start their own brokerage business, eventually convincing Sun-Diamond to
8 drop Plate and hire them instead. *Id.* at 1120–21. Plate brought suit against Sun-Diamond,
9 McElroy, Branson, and others, and Sun-Diamond agreed to bear the cost of litigation, share
10 its counsel, and indemnify them to the extent required by section 317 against liabilities
11 arising from the litigation. *Id.* at 1121. In concluding that defendants Branson and
12 McElroy were not sued “by reason of the fact” they were agents of Sun-Diamond for
13 indemnification purposes, the court explained that

14 [t]he record establishes these defendants were sued because of
15 activity undertaken to establish their own business entirely
16 independent of Sun-Diamond, for their own personal benefit, and
17 not in furtherance of Sun-Diamond’s policies or objectives. Such
18 activity was unrelated to the performance of their corporate
19 duties and responsibilities at Sun-Diamond. Indeed, Branson
20 testified that they delayed informing Sun-Diamond of their plans
21 because such plans would be viewed as creating a conflict of
22 interest with their job performance at Sun-Diamond. Branson
23 and McElroy thus were sued in their capacity as individuals
24 pursuing their personal interests, and not by reason of the fact
25 they were agents of Sun-Diamond. There simply is no evidence

26 between any of the underlying proceedings contemplated by section 145(e) and one’s official corporate
27 capacity, those proceedings are ‘by reason of the fact’ that one was a corporate officer, without regard to
28 one’s motivation for engaging in that conduct.” *Homestore, Inc. v. Tafeen*, 888 A.2d 204, 214 (Del. 2005).
Additionally, a causal connection exists if the official’s corporate powers “were used or necessary for the
commission of the alleged misconduct.” *Bernstein v. TractManager, Inc.*, 953 A.2d 1003, 1011 (Del. Ch.
2007). While Defendant urges the Court to adopt these standards, (Mot. 20, ECF No. 59-1), and the Court
finds Delaware law on advancement generally instructive for the reasons set forth above, *supra* note 3,
here there is at least some guidance from California courts. Thus the Court declines to adopt Delaware
law on this point and instead extends California indemnification law interpreting “by reason of the fact”
to the advancement analysis.

1 to support a finding that the first prerequisite to indemnification
2 under section 317, subdivision (b), was met.

3 *Id.* at 1126.⁷

4 Applying the logic of *Plate*, the Court concludes that Defendant was not sued “by
5 reason of the fact” that he was an agent and/or officer of Plaintiff. Specifically, all of
6 Plaintiff’s claims against Defendant appear to implicate actions that predominantly benefit
7 Defendant, but do not appear to be in furtherance of the corporate good or performed in
8 connection with Defendant’s corporate functions. Plaintiff’s claim for declaratory
9 judgment of patent application ownership is not an action against Defendant, but an action
10 to generally determine ownership of patent rights. (*See* SAC ¶¶ 45–48.); *see also Allergia,*
11 *Inc. v. Bouboulis*, No. 14-CV-1566 JLS (RBB), 2015 WL 11735654, at *5 (S.D. Cal. Aug.
12 17, 2015) (Sammartino, J.) (“Here, Plaintiff has shown that the parties disagree over the
13 ownership rights of the patent applications, and that such dispute warrants immediate
14 attention. A declaratory judgment by the Court, which would resolve the ownership
15 dispute, is necessary for Plaintiff and Defendant to effectively proceed with their business
16 ventures.”). Thus, this claim is not against Defendant at all, much less “by reason of the
17 fact” that he was an officer or agent of the corporation. Accordingly, the Court concludes
18 that this cause of action does not implicate the section 317 advancement analysis or any
19 right to advancement under Plaintiff’s Bylaws.

20 Furthermore, Plaintiff’s claims against Defendant for breach of fiduciary duty and
21 implied contract center on (1) Defendant’s failure to inform Plaintiff that he believed he
22 still owned some or all rights in the ’172 and ’672 patent applications, (SAC ¶¶ 50–51,
23 ECF No. 53), and (2) Defendant’s filing of allegedly secret and competing patent
24 applications and similarly not disclosing the same, (*id.* ¶ 52). Plaintiff’s assertions of fraud
25

26
27 ⁷ The *Plate* Court then discussed the second prerequisite to indemnification—whether the defendants acted
28 in good faith—and thus that analysis is not subsumed by the court’s discussion of “by reason of the fact.”
See Plate, 225 Cal. App. 3d at 1126.

1 against Defendant are based on these same allegations. (*Id.* ¶¶ 56–60.) The Court finds
2 that these claims for relief largely—if not entirely—implicate Defendant’s personal
3 motives, not the corporate good. Specifically, Defendant’s failure to inform Plaintiff that
4 he believed he owned some or all rights in the patent applications served to benefit him
5 (i.e., he might later assert, unbeknownst to Plaintiff, some claim for ownership rights in the
6 eventual patents). Likewise, Defendant’s alleged filing of secret and competitive patent
7 applications demonstrates a motive to retain sole ownership in those applications. And the
8 Court cannot discern how any of these alleged actions benefit Plaintiff in any way or were
9 performed by Defendant in furtherance of his corporate functions.

10 To be sure, the fact that Defendant signed certain documents transferring ownership
11 of the ’172 patent application to Plaintiff likely could not have been accomplished without
12 his role as interim President. And Defendant is accused of using his position as an officer
13 to obtain confidential information that may have been used in filing his secret patent
14 applications. Such allegations might entitle Defendant to advancement in Delaware—and
15 other—courts. *Supra* note 6. But based on the standard set forth in *Plate*, the Court
16 declines to conclude that the core of the allegations against Defendant—that he did not
17 disclose his belief that he still owned some or all rights in the ’172 and ’672 patent
18 applications, and that he secretly filed competing patent applications while working for
19 Plaintiff—were in furtherance of his corporate functions or the corporate good. *Cf. Warner*
20 *v. Sims Metal Mgmt.*, No. C 13-02190 WHA, 2013 WL 4777314, at *2 (N.D. Cal. Sept. 6,
21 2013) (in the indemnification context, finding that the plaintiff was not sued by reason of
22 the fact he was an agent where “defendant allege[d] that plaintiff converted property and
23 submitted fraudulent expense reimbursements, which are purely self-serving acts that do
24 not further the corporate good”). Accordingly, the Court **DENIES** Defendant’s Motion for
25 Advancement of Legal Expenses.⁸


26
27
28 ⁸ As a result, the Court need not address Plaintiff’s other arguments, such as public policy concerns or its
request to amend its SAC.

1 **CONCLUSION**

2 For the foregoing reasons, the Court **DENIES** Defendant's Motion for Advancement
3 of Legal Expenses. (ECF No. 59.)

4 **IT IS SO ORDERED.**

5 Dated: January 19, 2017

6 
7 Hon. Janis L. Sammartino
8 United States District Judge

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28